MET and lung carcinoma: Some HGF/MET inhibitors are currently used in the clinic, including crizotinib (suppresses the migration and invasion of the human NCI-H441 lung carcinoma cell), MK-2461 (a potent ATP-competitive inhibitor significantly reduces migration and tubulogenesis), and foretinib (EXEL-2880, which inhibits murine B16F10 melanoma cell migration and invasion).